Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
845
Total Claims
$4.0M
Drug Cost
143
Beneficiaries
$28K
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 3,372 Medical Oncology providers
+19%
Opioid rate vs peers
7.0% vs 5.9% avg
+130%
Cost per patient vs peers
$28K vs $12K avg
Opioid Prescribing
7.0%
Opioid Rate
59
Opioid Claims
$2,907
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 0 claims · $0
Generic: 537 claims · $62K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Pacritinib Citrate | 23 | $545K |
| Ruxolitinib Phosphate | 30 | $521K |
| Dasatinib | 27 | $458K |
| Belumosudil Mesylate | 21 | $379K |
| Azacitidine | 12 | $320K |
| Ibrutinib | 13 | $221K |
| Acalabrutinib Maleate | 12 | $183K |
| Zanubrutinib | 12 | $163K |
| Eltrombopag Olamine | 14 | $137K |
| Venetoclax | 25 | $60K |
| Apixaban | 22 | $19K |
| Rivaroxaban | 19 | $12K |
| Imatinib Mesylate | 18 | $5,751 |
| Hydroxyurea | 61 | $1,914 |
| Acyclovir | 56 | $782 |
Prescribing Profile
Patient Profile
63
Avg Age
48%
Female
3.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About